Skip to content

Role of guaiacum officinale in reduction of serum uric acid in patient of hyperuricemia

Assessing the role of guaiacum officinale in serum Uric acid reduction in hyperuricemia patients of Age group 40 to 70 a clinical pre and post treatment Evaluation - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080256
Enrollment
40
Registered
2025-02-10
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E790- Hyperuricemia without signs of inflammatory arthritis and tophaceous disease

Interventions

Intervention1: HOMOEOPATHIC MEDICINE GUAIACUM OFFICINALE: POTENCY VARIOUS DOSE AS PER NEED OF CASE FREQUENCY AS PER NEED OF CASE ROUTE OF ADMINISTRATION ORAL DURATION OF TREATMENT 8 MONTHS AS PER NEED

Sponsors

DR JINALBEN RAMESHKUMAR PRAJAPATI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: AGE GROUP 40 TO 70 YEARS Sex Male and Female Uric acid level 6 TO 9 mg dl in female and 7 TO 9 mg dl in male Patient who have been clinically diagnosed with Hyperuricemia Patient who gave voluntary consent to be include in the study A case showing symptoms similarity with the Guaiacum officinale

Exclusion criteria

Exclusion criteria: Patients suffering from severe gout rheumatoid arthritis osteoarthritis Patient who are taking allopathic ayurvedic or homoeopathic treatment for hyperuricemia

Design outcomes

Primary

MeasureTime frame
SERUM URIC ACID LEVEL TO ASSESS THE REDUCTION OF URIC ACID LEVEL AND SYMPTOMS OF HYPERURICEMIATimepoint: SERUM URIC ACID LEVEL WILL BE ASSESSED AT BASELINE AND AT THE END OF TREATMENT

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDR JINALBEN RAMESHKUMAR PRAJAPATI

SMT A J SAVLA HOMOEOPATHIC MEDICAL COLLEGE AND RESEARCH INSTITUTE

nisha.mehul.26@gmail.com9974342824

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026